Moderna vs Euro/US Dollar FX Spot Rate: why the prices moved differently

• ▲

  UAE investment and manufacturing talks Moderna's chairman met UAE officials to discuss investment and pharma manufacturing cooperation. This could fund expansion and open a new market, pushing the stock to a four-year high of $195.71. It shows the company is building beyond COVID.

  New event that directly lifted the stock to a multi-year high and signals growth beyond COVID.

• ▲

  Nasdaq 100 index inclusion Moderna will join the Nasdaq 100 on October 9, replacing Warner Bros. Discovery. Index funds that track the Nasdaq 100 must buy the stock, creating automatic demand. This often lifts a stock's price and adds credibility.

  New event that creates forced buying by index funds, a direct positive for the stock price.

• ▼

  Citi downgrade to sell on valuation Citi downgraded Moderna to sell, saying the stock's valuation is unjustifiable after the cancer vaccine win. The price target is 60% below the prior close. This warns that the stock may have run too far, too fast, and it fell over 6%.

  New analyst action that directly pushed the stock down and highlights valuation risk.

• ▼

  Monsanto mRNA patent lawsuit proceeds A judge rejected Moderna's bid to dismiss Monsanto's patent infringement lawsuit over its COVID vaccine. The case will continue, creating legal uncertainty and potential financial liability. This is a real counterweight to the recent good news.

  New legal development that adds uncertainty and potential cost, weighing on the stock.

Based on 8 stories →

• ▲

  FDA panel backs mRNA flu shot An FDA advisory panel voted unanimously that Moderna's mRNA flu shot, mFlusiva, is safe and effective for adults 50 and older. This clears a key regulatory hurdle and opens a second big market beyond COVID, supporting the stock.

  This is a new regulatory milestone that expands Moderna's commercial opportunity.

• ▲

  Bird flu vaccine enters Phase 3 Moderna started a late-stage trial of its mRNA bird flu vaccine with backing from an international pandemic group. It shows the mRNA platform can target new infectious diseases, adding another potential long-term growth driver.

  This is a new pipeline advancement that broadens the platform's application.

• ▲

  Cancer vaccine Phase 3 success confirmed Moderna and Merck's personalized mRNA cancer vaccine met its main goal in a large melanoma trial, cutting recurrence risk. This is the first late-stage win for an mRNA cancer therapy, opening a potential multi-billion-dollar market and driving the stock sharply higher.

  This is the core new event that re-rates Moderna's growth story.

• ▲

  Stock extends rally on cancer data MRNA jumped 6% to $154, extending a 137% one-month rally, as investors continued to bet on the melanoma vaccine data. No new company news drove the move, but the market is rewarding Moderna's specific cancer asset over rivals.

  This shows the market's ongoing positive reaction to the cancer vaccine news.

Based on 6 stories →

• ▲

  FDA approves updated COVID and first mRNA flu shots Moderna won FDA approval for updated Spikevax and mNEXSPIKE COVID vaccines and mFlusiva, the first mRNA flu shot for adults 50+. This expands its sellable respiratory portfolio, though annual uptake and pricing will decide how much it really adds.

  New regulatory approvals directly expand Moderna's product lineup and revenue potential.

• ▲

  GSK's mRNA flu vaccine advance validates platform GSK said it will move its mRNA flu vaccine into Phase III after positive Phase II results. Investors saw this as proof that mRNA works for flu, not as a threat, and Moderna shares rose nearly 10% on the news.

  A rival's progress independently validates the mRNA platform Moderna is built on.

• ▲

  August surge and $2B raise show investor conviction Moderna ended August up 156%, the top S&P 500 performer, after the melanoma trial win. It also raised $2 billion in convertible notes for its cancer vaccine business, and hedge fund holdings rose 10% to $1.5 billion.

  Confirms the cancer breakthrough is translating into real capital and sustained investor backing.

Based on 6 stories →

• ▲

  First mRNA cancer vaccine clears Phase 3 Moderna and Merck's personalized mRNA cancer vaccine, intismeran, met its main goal in a 1,137-patient melanoma trial, cutting recurrence versus Keytruda alone. This is the first late-stage win for an mRNA cancer therapy, opening a potential new market beyond vaccines and sending MRNA up as much as 177%.

  This is the single biggest new event of the period and the core reason MRNA moved.

• ▲

  Analyst upgrades and huge sales forecasts William Blair upgraded Moderna to Outperform and Wolfe Research to peer perform, while forecasts for intismeran peak sales range from $1.4 billion (Leerink) to $16.8 billion (Morningstar) by 2035. These signal professional investors see the cancer win as a durable business driver, not just a one-day pop.

  Upgrades and forecasts show whether the cancer win is treated as lasting value, which drives the stock beyond the initial spike.

• ▼

  $2.6B convertible note raise dilutes and pressures stock Moderna plans to raise $2.6 billion via convertible notes due 2032 for its cancer vaccine business and debt repayment. Convertible notes can dilute existing shareholders if converted, and the stock fell about 5% premarket and 4% intraday on the news, a real counterweight to the rally.

  This is the main new negative force this period and explains why MRNA fell for three straight sessions.

• ◆

  BioNTech's trial failure cuts both ways BioNTech halted a Phase 2 mRNA cancer vaccine trial in colorectal cancer for futility, sending its shares down 10% and dragging Moderna lower on negative read-across. But the failure also highlights Moderna's melanoma success, where it targeted a 'hot' tumor with Keytruda, strengthening its competitive position.

  This is a new event that both pressures MRNA via sector sentiment and supports its relative advantage.

Based on 23 stories →

• ▲

  First mRNA cancer vaccine wins Phase 3 Moderna and Merck's personalized mRNA cancer vaccine, intismeran, met its main goal in a large melanoma trial, cutting recurrence versus Keytruda alone. This is the first late-stage win for an mRNA cancer therapy, opening a potential new market beyond vaccines and sending MRNA up as much as 177%.

  This is the core new event that explains the period's massive move and changes Moderna's long-term growth story.

• ▲

  Analysts upgrade and raise sales forecasts BofA upgraded Moderna to Neutral with a $170 target and lifted its peak sales estimate for intismeran to $54 billion, while William Blair moved to Outperform. These upgrades signal that professional investors see the cancer win as a real, durable business driver, not just a one-day pop.

  Analyst upgrades and raised forecasts show the market is repricing Moderna's future revenue, which supports the stock beyond the initial spike.

• ▼

  Sharp pullback after record surge After the record 177% jump, MRNA fell about 20-23% the next day as some investors took profits. Such a violent swing shows the stock is now very volatile and that not everyone believes the rally is justified, which can scare off cautious investors.

  The pullback is a real counterweight to the positive news and shows the risk that the stock has run far ahead of fundamentals.

• ◆

  Valuation gap and short-seller pain Even after the surge, the average analyst price target is only about $44, far below the last close near $133, suggesting the stock may be overvalued. Short sellers lost about $5.5 billion, which can fuel further sharp moves in either direction as positions unwind.

  This highlights the tension between the exciting science and the stock's stretched valuation, a key risk for new investors.

Based on 20 stories →

• ▲

  FDA approves first mRNA flu vaccine Moderna won FDA approval for mFLUSIVA, the first mRNA-based flu vaccine, for adults 50 and older. This is a major milestone: a new product to sell and proof its mRNA technology works beyond COVID, which can lift the stock.

  This is the biggest new event, directly adding a new product and validating the platform.

• ▼

  Norovirus vaccine fails interim analysis Moderna's norovirus vaccine candidate did not meet early success criteria in a Phase 3 interim analysis, and the company will enroll more patients. This is a pipeline setback that can weigh on the stock by raising doubts about other vaccine programs.

  This is a new negative event that offsets the flu approval and affects pipeline sentiment.

• ▲

  Ebola vaccine trial starts Moderna began a Phase 1 trial of an Ebola vaccine for a strain with no approved shot, backed by up to $50 million from CEPI. It shows the mRNA platform can target new diseases, supporting the long-term growth story even if revenue is years away.

  This is a new pipeline milestone that broadens the platform's potential beyond COVID and flu.

• ▼

  Arbutus settlement payment Arbutus received a $178 million payment from Moderna as part of a $950 million patent settlement. This is cash leaving Moderna and a reminder that legal costs from past patent disputes continue to weigh on finances.

  This is a new cash outflow event that affects Moderna's financial position.

Based on 6 stories →

• ▲

  Q2 earnings beat and outlook reaffirmed Moderna beat second-quarter revenue and loss estimates and reaffirmed its full-year growth target. This shows the business is performing better than expected, which supports the stock price by reducing fears about cash burn and future funding needs.

  This is the main new financial event of the period and directly affects investor confidence in MRNA.

• ▲

  FDA decision on mRNA-1010 flu vaccine due August 5 An FDA ruling on Moderna's standalone flu shot is expected within days. Approval would give Moderna a fifth commercial product and help rebuild its respiratory vaccine business, potentially lifting the stock if the decision is positive.

  This is a near-term regulatory catalyst that could significantly change MRNA's product lineup and revenue outlook.

• ▼

  Norovirus vaccine trial misses early metric Moderna's norovirus vaccine trial missed an early goal, disclosed alongside earnings. This is a setback for a pipeline candidate and may dampen enthusiasm about the company's broader vaccine prospects, weighing on the stock.

  This is a new negative development that tempers the positive earnings news and highlights pipeline risk.

• ▲

  Strong Q1 revenue growth and AI ranking Moderna's Q1 revenue surged 260% year-over-year, the fastest among therapeutics stocks, and it ranked third in an investor survey of AI integration. These reinforce the growth narrative and positive sentiment, though the AI angle is not a major valuation driver.

  This provides context on Moderna's recent financial momentum and investor perception, supporting the bull case.

Based on 7 stories →

• ▲

  Analyst upgrade and Cramer's bullish turn Piper Sandler raised its price target, and Jim Cramer said Moderna is investable again, citing the pipeline shift into cancer, rare diseases, and a new flu shot. These endorsements drew new buyers, pushing the stock up sharply.

  New analyst and media endorsements directly lifted investor sentiment and the stock price.

• ▲

  Science Day fuels mRNA expansion hopes Moderna's Science Day showcased plans to move beyond vaccines into cancer therapies, autoimmune treatments, and an in vivo CAR-T candidate. Investors saw a broader future beyond COVID, driving the stock to a 52-week high and adding billions in market value.

  The Science Day event was a major catalyst that expanded the growth story and attracted investors.

• ▼

  Vaccine skepticism resurfaces Renewed political focus on vaccine skepticism sent Moderna shares down nearly 11% in one day. This shows that political and public-health headwinds can still hit the stock hard, even as the pipeline improves.

  This is a new negative development that highlights a real risk to Moderna's core vaccine business.

• ▼

  Patent settlement cash outflow Moderna paid $178 million to Arbutus as part of a patent settlement. While the amount is smaller than earlier settlements, it is still cash out the door and a reminder that legal costs continue to weigh on finances.

  This new payment is a concrete financial hit and shows ongoing litigation costs.

Based on 6 stories →

• ▲

  Science Day showcases pipeline beyond COVID Moderna's Science Day highlighted progress in cancer, autoimmune, and next-generation mRNA treatments, including its first cancer prevention program and a multiple sclerosis therapy. This expands the company's potential beyond COVID vaccines, giving investors new reasons to believe in future growth and pushing the stock up.

  This is the main new event of the period and directly explains the stock's surge.

• ▲

  FDA panel backs flu vaccine, approval decision in August An FDA advisory panel voted 9-0 in favor of Moderna's mRNA flu vaccine for adults 50 and older, making final approval by August 5 much more likely. A new revenue stream would reduce reliance on COVID vaccines, boosting investor optimism and the stock price.

  This is a new regulatory milestone that de-risks a key product and supports the stock's rise.

• ▲

  Strong Q1 revenue growth beats expectations Moderna's first-quarter revenue jumped 260% year over year to $389 million, beating analyst estimates by 55.8%. This shows the business is growing faster than expected, which supports the stock price even though the company still posted a loss.

  This new earnings data provides fundamental support for the stock's recent gains.

• ◆

  Analysts still cautious despite strong run Even after the stock surged nearly 42% in a month, Quant Ratings, Seeking Alpha analysts, and Wall Street analysts maintain a Hold rating. This suggests that while the pipeline is promising, significant risks remain, which could limit further upside or lead to pullbacks.

  This provides a fair counterweight to the positive news and explains why the stock isn't rated a buy.

Based on 7 stories →

• ▲

  FDA panel unanimously backs Moderna's flu vaccine An FDA advisory committee voted 9-0 that Moderna's mRNA flu vaccine is safe and effective for adults 50 and older. This key endorsement makes approval by the August 5 deadline much more likely, opening a new revenue stream and boosting investor confidence.

  This is the main new event that directly lifts MRNA's price by de-risking a major product approval.

• ▲

  Moderna plans three new vaccine launches by 2028 Moderna said it will launch a combined flu-COVID shot, a seasonal flu vaccine, and a norovirus vaccine between 2027 and 2028. It also expects important trial results this year for a personalized cancer therapy and a rare disease treatment, which could lead to its first oncology and rare disease products.

  This new pipeline update shows future growth beyond COVID vaccines, supporting a higher stock price.

• ▼

  Moderna to pay $2.25 billion in patent settlement Moderna agreed to a $2.25 billion global settlement with Roivant Sciences to resolve patent-infringement litigation. This is a large cash outflow that reduces Moderna's financial flexibility and is a real cost, even though it removes a legal cloud.

  This new settlement is a significant negative financial event that weighs on MRNA's price.

Based on 7 stories →

• ▼

  French debt crisis and political gridlock sink euro Investors are dumping French bonds and stocks as public debt heads toward 120% of GDP, pushing the French-German bond spread to 141 basis points. This political and fiscal risk makes the euro less attractive, pushing EURUSD down to its lowest since May 2025.

  This is the main new force driving the euro lower this period.

• ▼

  US bond yields surge, Fed rate hike bets rise US 10-year Treasury yields jumped above 5.2%, the highest since 2002, as oil prices climbed and Fed officials backed further rate hikes. Higher US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down.

  This is a key new driver of dollar strength this period.

• ▲

  Eurozone inflation beats forecasts, keeping ECB hike pressure alive Eurozone September inflation rose to 3.8%, above the 3.6% forecast, with core inflation up to 2.5%. This keeps pressure on the ECB to raise rates further, which supports the euro by attracting global money into euro deposits.

  This is a new counterweight that could support the euro despite the negative drivers.

• ▼

  Energy shock and political risk weigh on euro outlook European gas prices above €80/MWh and the war in Iran disrupting LNG shipments are hurting Europe's economy. Meanwhile, far-right gains in Germany and France's political gridlock add uncertainty. These factors make the euro less attractive, pushing EURUSD down.

  This explains the broader negative backdrop for the euro this period.

Based on 8 stories →

• ▲

  Eurozone economy unexpectedly strong, supports euro The eurozone's business activity index jumped to 53.1 in September, the highest in over three years, beating expectations. A stronger economy makes the euro more attractive and supports further ECB rate hikes, pushing EURUSD up.

  This is new data showing eurozone resilience, which strengthens the euro.

• ▲

  ECB officials hint at more rate hikes to fight inflation ECB's Nagel said rates may need to become restrictive, and Makhlouf said the ECB would act if energy prices spill over. BofA expects a December hike. Higher expected euro rates attract global money, pushing EURUSD up.

  New hawkish comments from ECB officials and BofA's forecast reinforce expectations of higher euro rates.

• ▼

  US bond yields surge and Fed officials back more hikes The 10-year US Treasury yield rose above 5%, the highest in 19 years, after strong US business activity data. Fed's Collins, Musalem, and Barr supported further rate hikes. Higher US rates make the dollar more attractive, pushing EURUSD down.

  New US data and Fed comments drive dollar strength, a key counterweight to the euro.

• ▼

  German political risk and ECB's Lane downplays wage pressure Germany's far-right party won a major regional election, weakening the coalition and raising political uncertainty. ECB's Lane said no strong wage pressure, suggesting fewer hikes. These factors weigh on the euro, pushing EURUSD down.

  New political and monetary developments that could undermine euro strength.

Based on 11 stories →

• ▲

  Markets price more ECB hikes; banks see 2.75% or higher Money markets now price more than four additional ECB hikes, and banks like Barclays, Goldman and Rabobank expect another 25bp move in December to 2.75%. Expectations of higher-for-longer euro rates attract foreign capital into the euro, supporting EURUSD.

  Shows how far investors expect euro rates to rise, a key support for the euro.

• ▼

  Fed hikes to 3.75-4.00%, first rise in three years The Fed raised rates on September 16, six days after the ECB, and strong US retail sales and 3.4% inflation backed the move. Higher US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down to about 1.1450.

  The Fed's hike is the main new force pulling EURUSD down this period.

• ◆

  Oil and gas above ECB assumptions keep inflation high Brent above $100 and natural gas above €83/MWh exceed the ECB's worst-case assumptions, so inflation may stay high longer. This keeps the ECB tightening, which supports the euro, but high energy also hurts Europe's growth and can push investors to the dollar.

  Energy prices are the underlying force driving both ECB tightening and euro weakness.

Based on 24 stories →

• ▲

  ECB delivers first hike in two meetings, signals more The ECB raised its deposit rate to 2.50% on September 10, its second hike this year, and said inflation will stay above target through 2028. Higher euro interest rates attract global money into the euro, pushing EURUSD up. Markets now expect at least one more hike by year-end.

  The ECB's actual rate hike and further-hike signal is the main new force lifting the euro.

• ▲

  Eurozone economy resilient, ECB raises growth forecast ECB President Lagarde said she was surprised by the economy's resilience, with defense, infrastructure and AI investment supporting growth. The ECB raised its 2026 growth forecast to 0.9%. A stronger economy makes the euro more attractive and supports further rate hikes, pushing EURUSD up.

  Economic resilience gives the ECB room to keep rates high, reinforcing euro strength.

• ▼

  US rate-hike odds jump on hot PPI, capping euro US producer price inflation rose 5.4% in August, above expectations, and markets now price a 70% chance of a Fed hike on September 16, up from 61%. Higher expected US rates make dollar deposits more attractive, strengthening the dollar and limiting EURUSD's rise.

  This is the main counterweight: US rate expectations are rising too, which caps the euro's gains.

• ▲

  Oil above $100 fuels inflation, keeping ECB hawkish Brent crude surged past $105 as Middle East conflict cut energy exports, pushing eurozone inflation to 3.3%. The ECB hiked to prevent energy costs spreading. While high oil can hurt growth, it keeps the ECB tightening, which supports the euro against the dollar.

  Oil-driven inflation is the reason the ECB is hiking, directly linking energy prices to euro strength.

Based on 7 stories →

• ▲

  Eurozone inflation jumps, ECB hike bets build Eurozone inflation rose to 3.3% in August from 2.9%, driven by energy, and producer prices jumped 5.8%. Officials like Holzmann and Nagel pushed for more tightening, and markets now price a September ECB hike with near certainty. Higher expected euro interest rates pull global money into the euro, pushing EURUSD up.

  Rising euro-area inflation and hawkish ECB signals are the main new force lifting the euro.

• ▲

  Banks see ECB hiking further, rates staying higher JPMorgan and BNP Paribas now expect an extra ECB hike in December, and DBS sees the deposit rate at 2.50%, citing sticky inflation and resilient growth. Expectations of higher-for-longer euro rates attract foreign capital into the euro, supporting EURUSD.

  New forecasts of further ECB tightening extend the rate advantage that supports the euro.

• ▼

  US euro-selling intervention and Fed pushback weigh on euro European central bankers are frustrated that the US sold euros to buy yen without warning, and Bundesbank's Nagel called it a surprise. The extra euro supply weakens the euro. Meanwhile, Fed's Waller backed holding US rates, and strong August US jobs raised hike odds, both supporting the dollar and pushing EURUSD down.

  This is the main counterweight: US policy actions and data that strengthen the dollar against the euro.

• ◆

  ECB's blockchain euro plan could support long-term demand ECB's Schnabel pushed for issuing a blockchain-based euro, rejecting stablecoins, with the Pontes project launching next month. If it makes the euro more useful in digital finance, it could gradually raise demand for euros. But the effect is long-term and small for now, so it is a minor support.

  A new structural initiative that could affect future euro demand, though not an immediate price driver.

Based on 12 stories →

• ▲

  ECB September rate hike increasingly expected The ECB is set to raise its policy rate to 2.50% in September to stop war-driven energy inflation spreading, and official Schnabel said more tightening is needed. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

  A near-certain ECB hike is the main force lifting the euro this period.

• ▼

  Fed Chair Warsh hints at a US rate hike At Jackson Hole, Fed Chair Warsh said there is 'work to do' on inflation, lifting the chance of a September US hike to about 57.5% from 35%. Higher expected US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down.

  This is the main new counterweight that pulled the euro back from its highs.

• ▼

  Hot US inflation surprise supports the dollar A hotter-than-expected US PCE inflation reading on August 27 pushed US rates and the dollar up, sending EURUSD to about 1.1650. Stronger US inflation keeps the Fed from easing, which supports the dollar and weighs on the euro.

  It shows the US side of the rate story that is capping the euro.

• ▼

  US-Japan currency alliance keeps selling euros Citi says the US-Japan interventions reflect an informal currency alliance, with Washington selling euros to buy yen and possibly acting again if EUR/JPY nears 185-186. Extra euro supply in the market weakens the euro against the dollar.

  It is a real, ongoing drag on the euro that readers should not overlook.

Based on 10 stories →

• ▲

  Fed rate-hike bets collapse, dollar loses its yield appeal US jobs data stayed weak and the Fed kept rates unchanged with a split committee, so traders cut the chance of a September hike to about 35% from 52% a week earlier. Lower expected US interest rates make dollar deposits less attractive, pushing EURUSD up.

  This is the main new force weakening the dollar and lifting the euro this period.

• ▲

  US Treasury buybacks and Middle East de-escalation weaken the dollar The US Treasury said it would more than double its bond buybacks to add market liquidity, which pushed the dollar down broadly and the euro up to about 1.166. Progress in Iran talks to reopen the Strait of Hormuz also cut safe-haven demand for the dollar.

  These are new events that directly weakened the dollar and pushed EURUSD to a two-month high.

• ▲

  Eurozone economy strengthens, keeping ECB hike on the table Eurozone business activity hit its highest since last November, with new orders growing fastest in 40 months and hiring rising for the first time this year. ECB official Lane said 3% inflation is too high. A stronger economy and likely ECB hike attract money into the euro.

  New eurozone data and ECB comments support the euro side of the pair.

• ▼

  Counterweight: consumers see lower inflation, and Middle East risk lingers Eurozone consumers' inflation expectations fell for a third month, which could soften the ECB's willingness to hike and cap the euro. Iran also threatened a fully offensive military posture after talks stalled, which could revive safe-haven dollar demand and push EURUSD down.

  This is the real counterweight that could stop the euro's rise, so readers get a fair picture.

Based on 24 stories →

• ▲

  ECB signals September hike, lifting euro The ECB held its key rate at 2.25% but strongly hinted at a September hike, and markets now price the deposit rate near 2.7% by year-end and 3% by 2027. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

  This is the main new force lifting the euro this period.

• ▼

  US-Japan joint intervention sells euros for yen The US and Japan jointly intervened to support the yen, selling euros to buy yen in a roughly $87 billion operation. This directly increased the supply of euros in the market, pushing the euro down against the dollar and adding geopolitical risk.

  This is a new, direct supply shock to the euro that weighs on EURUSD.

• ◆

  US data mixed: weak jobs, strong ISM and hawkish Fed Weak US jobs and soft data weakened the dollar, but strong ISM manufacturing and hawkish Fed comments later supported it. The tug-of-war between US rate-hike and rate-cut expectations keeps EURUSD volatile, with no clear direction from US data alone.

  US data is a key counterweight to the euro's rise, and its mixed nature explains the back-and-forth.

• ▲

  Eurozone GDP beats, supporting ECB hike case Eurozone second-quarter GDP rose 0.4%, beating forecasts, and business activity was strong. This supports the case for an ECB rate hike in September, making the euro more attractive to global investors and helping push EURUSD higher.

  Strong eurozone growth reinforces the ECB tightening story that lifts the euro.

Based on 24 stories →

• ▲

  Weak US jobs report kills Fed rate-hike bets, lifting euro US July payrolls unexpectedly fell by 23,000, the first drop in five months, and wage growth slowed. Traders slashed the chance of a September Fed rate hike to about 44% from 58%. Lower expected US interest rates weaken the dollar, pushing EURUSD up to a seven-week high near 1.157.

  This is the main new force this period: a weak US economy makes the dollar less attractive, directly lifting the euro.

• ▼

  US sells euros to buy yen, weakening euro The US Treasury intervened to support the yen by selling euros and buying yen, without telling the ECB first. This directly increased the supply of euros in the market, pushing the euro down against the dollar. The ECB called it shocking, raising fears of strained central-bank cooperation.

  This is a new, direct action that weakens the euro and is a real counterweight to the euro's rally.

• ▲

  Strong German trade data supports euro German trade data came in better than expected, adding to signs that Europe's largest economy is holding up. A stronger eurozone economy makes the euro more attractive to global investors, helping push EURUSD higher alongside the weak US jobs news.

  It is a new eurozone-specific factor that supports the euro and helps explain the move to a seven-week high.

Based on 8 stories →

• ▲

  Fed holds rates, dollar falls broadly The Fed kept its key rate at 3.50–3.75% for a fifth straight meeting, with only three members wanting a hike. Because US rates are not rising, the dollar lost its appeal and fell, pushing EURUSD up to about 1.143.

  A steady Fed directly weakens the dollar, the main force lifting EURUSD this period.

• ▲

  Weak US GDP and cooling PCE knock dollar to six-week low US second-quarter GDP grew only 1.5%, below the 2.0% forecast, and core PCE inflation eased to 3.3%. Slower US growth and softer inflation mean the Fed is less likely to hike, weakening the dollar and lifting the euro to a six-week high.

  Soft US data reduce expected US rates, a key driver of dollar weakness and euro strength.

• ▲

  Eurozone GDP and confidence beat, inflation accelerates to 2.9% Eurozone second-quarter GDP rose 0.4% and economic confidence hit a five-month high, while July inflation accelerated to 2.9% on higher oil. Stronger growth and sticky inflation strengthen the case for ECB rate hikes, supporting the euro.

  Better eurozone data and higher inflation raise ECB hike odds, boosting the euro's rate appeal.

• ▼

  Trump tariff threat and oil spike weigh on euro Trump threatened steep tariffs on the EU after Brussels fined Google $1 billion, and Brent crude jumped over 6% on Iran tensions. Tariffs and costlier energy hurt the eurozone economy, a counterweight that could cap the euro's gains.

  This is the main risk pulling EURUSD down, balancing the positive drivers.

Based on 6 stories →

• ▲

  ECB signals possible September hike as oil-driven inflation risks rise The ECB held its key rate at 2.25% but President Lagarde strongly hinted at a September hike, calling inflation risks tilted to the upside. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

  This is the main new monetary policy event of the period and directly supports the euro.

• ▲

  German 10-year bond yield hits 15-year high on ECB hike expectations Germany's 10-year yield surged to 3.21%, the highest since 2011, as markets priced two more ECB hikes by early 2027. Higher euro-area bond yields make euro deposits more attractive, lifting the euro against the dollar.

  Rising euro yields are a key channel through which ECB hike bets strengthen the euro.

• ▼

  Oil above $100 and Middle East attacks boost dollar safe-haven demand and Fed hike bets Houthi attacks on Saudi tankers sent Brent above $100, reigniting US inflation fears. Markets now price an 83% chance of a September Fed hike, up from 52% a week ago. Higher US rates and safe-haven flows strengthen the dollar, pushing EURUSD down.

  This is the main new force pulling EURUSD lower and is the counterweight to the ECB story.

• ◆

  SocGen warns oil spike may force ECB hikes but also sap eurozone growth Societe Generale says surging oil and gas could push the ECB to hike to 2.50% in September, but the same energy costs hurt eurozone growth. The bank sees a return above 1.1480 as a big ask, so the net effect on EURUSD is unclear.

  It fairly presents the real counterweight: higher energy prices can both help and hurt the euro.

Based on 12 stories →

• ▲

  Soft US CPI and PPI crush Fed rate-hike bets, lifting the euro US June consumer and producer inflation came in below forecasts, so traders slashed the chance of a Fed rate hike this month from 42% to 16% and for the year from 89% to 80%. Lower expected US rates weaken the dollar, pushing EURUSD up to a 3.5-week high near 1.1485.

  This is the main new force this period: softer US inflation directly reduces the dollar's rate advantage, a key driver of EURUSD.

• ◆

  Oil surge from Iran conflict cuts both ways for euro Renewed US-Iran fighting and sanctions sent oil up 9%, raising inflation fears. This could force the Fed to hike (dollar-positive) but also revives ECB hike bets (euro-positive). ING warns euro gains may stall above 1.1460 if oil keeps rising, as costlier energy hurts the eurozone economy.

  Oil is a major new factor this period, with a two-sided impact on EURUSD that explains why the euro's rally is capped.

• ▲

  ECB officials signal readiness to act, supporting euro ECB's Holzmann said no second-round inflation effects yet but the bank stands ready to act; Nagel urged caution but decisiveness if needed; Rabobank and ING note oil revives ECB hike risk. This keeps euro interest-rate appeal alive, underpinning EURUSD.

  ECB policy stance is a core driver of the euro's value versus the dollar, and this period brought fresh signals.

• ▼

  Eurozone inflation slows, ECB expected to hold rates Final June eurozone inflation was 2.8%, down from 3.2%, with core at 2.4%. Nordea expects the ECB to hold rates at its July meeting as a pause, not a pivot. Slower inflation reduces pressure to hike, limiting euro upside.

  This is a counterweight to the euro-positive ECB signals, showing why the euro isn't rising more.

Based on 21 stories →

• ▲

  ECB signals more rate hikes, supporting euro ECB minutes showed inflation will stay above target until 2027, and markets now price nearly three rate hikes. Higher euro interest rates attract global capital, pushing EURUSD up.

  This is a key new driver: ECB's hawkish stance strengthens the euro.

• ▲

  Middle East tensions weaken dollar, lift euro US-Iran ceasefire broke down, with US strikes on Iran. The dollar usually weakens on such geopolitical risk as investors avoid US assets, helping EURUSD rise.

  New escalation in Middle East tensions is a fresh factor pushing the dollar down.

• ▲

  Strong German data boosts euro German industrial production and exports rose unexpectedly in May, signaling eurozone economic resilience. A stronger economy supports the euro, pushing EURUSD higher.

  New positive economic data from Germany supports the euro.

• ◆

  Fed rate hike bets ease, but volatility may rise Weak US jobs data and stable claims reduced Fed hike odds, weakening the dollar. However, rising FX volatility and hedging demand could cause sharp swings in EURUSD.

  This shows a counterweight: while Fed bets ease, volatility risk remains.

Based on 14 stories →

• ▼

  Eurozone inflation cools, ECB hike bets fade Eurozone inflation slowed to 2.8% in June, below the 3% forecast, and German inflation also cooled. Traders cut bets on another ECB rate hike, reducing the euro's interest-rate appeal and pushing EURUSD down toward 1.1400.

  This is the main new force weakening the euro this period.

• ▲

  Weak US jobs data dents Fed hike expectations US June payrolls rose only 57,000, far below the 113,000 expected, and May's figure was revised down. This cooled bets on near-term Fed tightening, weakening the dollar and lifting the euro to a 1.5-week high above 1.1400.

  This is the main new force supporting the euro at the end of the period.

• ◆

  ECB still hawkish, but oil slump complicates ECB President Lagarde defended June's rate hike as necessary, and ING expects one more hike, supporting the euro. But lower oil prices reduce inflation pressure, and Commerzbank warns the ECB may not need to tighten much more, creating mixed signals.

  Shows the counterweight: ECB hawkishness supports the euro but may be fading.

Based on 18 stories →

• ▼

  Fed rate-hike bets drive dollar to 13-month high, euro below 1.14 The Fed under Kevin Warsh is expected to raise rates as soon as September, pulling global money into the dollar. The euro fell below 1.1400 to a one-year low near 1.1350, as higher US rates make dollar deposits more attractive than euro ones.

  This is the main force pushing EURUSD down this period.

• ▼

  Oil price collapse cuts ECB hike odds, weakening euro support Easing US-Iran tensions and restored Hormuz oil flows sent Brent crude from $115 in May to about $75. Lower energy costs reduce inflation pressure, so traders slashed the chance of a second ECB rate hike from 50% to 20%, removing a key euro support.

  This new oil-driven shift in ECB expectations is a fresh negative for the euro.

• ▼

  ECB's Lagarde downplays inflation, signaling no aggressive tightening ECB President Lagarde said the inflation shock needs only a measured response and no forceful action, even as Eurozone PMIs stay weak with German services at a 43-month low. This contrast with the hawkish Fed widens the euro-dollar interest rate gap, pushing EURUSD down.

  Lagarde's stance is a new, direct driver of euro weakness this period.

• ▲

  Dollar rally may be overdone; lower oil and weak US data spark rebound On Friday the dollar fell for a second day as lower oil and weak US consumer sentiment cooled Fed hike expectations, lifting the euro 0.43% to 1.1418. Analysts warn the dollar-positive loop may burn out, and BofA still sees euro recovery later in 2026 on German fiscal stimulus.

  This is the real counterweight that could stop or reverse the euro's fall.

Based on 24 stories →

• ▼

  Fed's hawkish turn under Warsh lifts USD, sinks EUR New Fed Chair Kevin Warsh's first meeting delivered a hawkish dot plot: nine of 19 officials now expect at least one rate hike by year-end. Higher US rates attract global capital to the dollar, pushing EURUSD down to a three-month low near 1.1416.

  This is the dominant new force this period, directly driving the euro to multi-month lows.

• ▼

  ECB hikes alone as other central banks hold The ECB raised rates and signaled more to come, but the BoE, SNB, Norges Bank and Riksbank stayed on hold. A lone hiker with weaker regional growth undermines the euro, as markets price downside risks for the euro area.

  Explains why ECB hikes are not supporting the euro, a key counterintuitive driver.

• ▲

  US-Iran peace deal briefly lifts euro Trump signed a memorandum with Iran to end the war, easing geopolitical tensions and weakening the safe-haven dollar. The euro rebounded above 1.1500, though the gain was short-lived as Fed rate expectations soon reasserted themselves.

  Shows a real counterweight to dollar strength, even if temporary.

• ◆

  Analysts warn dollar rally may be overdone ING cautioned the dollar's surge may not last, arguing the US-Iran deal removes a positive argument for the dollar and markets overestimate the chance of a Fed rate hike. This suggests EURUSD could stabilize or rebound if rate-hike bets fade.

  Provides a fair counterpoint that the dominant dollar-strength trend may reverse.

Based on 13 stories →